BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments
BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments
02/10/21, 1:07 PM
Location
san carlosMoney raised
$19 million
Round Type
series a
BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors. As part of the investment, Andreessen Horowitz General Partner, Vineeta Agarwala, MD, PhD joins BigHat’s Board of Directors.
Company Info
Location
san carlos, california, united states
Additional Info
ABOUT BIGHAT BIOSCIENCES
Founded in 2019 and headquartered in San Carlos, CA, BigHat Biosciences is developing an AI-guided protein therapeutic design platform that integrates a high-speed antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by 8VC, Andreessen Horowitz, AME Cloud Ventures, and Innovation Endeavors. Find BigHat Biosciences online: https://www.bighatbio.com/